{"preliminary_commentary":{"by_channel":{"x_thread":45,"youtube":16,"bluesky_thread":3,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04266249\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"CompassHER2-pCR","nct_id":"NCT04266249","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=compassher2-pcr-nct04266249. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nSURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.\n\nPOST-OPERATIVE.ADJUVANT THERAPY: Patients with pCR after surgery receive trastuzumab and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo standard of care radiation therapy and receive hormone therapy if appropriate.","label":"Arm A (pCR after surgery)","type":"EXPERIMENTAL"},{"description":"PRE-OPERATIVE/NEOADJUVANT THERAPY: Patients receive either paclitaxel or nab-paclitaxel IV on days 1, 8 and 15, or docetaxel IV on day 1 at the discretion of the treating oncologist. Patients also receive trastuzumab IV on day 1 or days 1, 8, and 15, and pertuzumab IV on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nSURGERY: Within 42 days after last dose of neoadjuvant therapy, patients undergo standard of care lumpectomy and/or mastectomy.\n\nPOST-OPERATIVE/ADJUVANT THERAPY: Patients with remaining tumor after surgery receive standard of care trastuzumab emtansine for 14 doses in the absence of disease progression or unacceptable toxicity. Patients may also receive additional standard of care chemotherapy, as well as hormone therapy if appropriate.","label":"Arm B (residual invasive disease after surgery)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2038-12-31","type":"ESTIMATED"},"conditions":["Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage IIA Breast Cancer AJCC v8","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Invasive Breast Carcinoma","Prognostic Stage II Breast Cancer AJCC v8","Prognostic Stage IIA Breast Cancer AJCC v8","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8"],"enrollment":{"count":2175,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Docetaxel","otherNames":["Docecad","RP56976","Taxotere","Taxotere Injection Concentrate"],"type":"DRUG"},{"name":"Lumpectomy","otherNames":["Lumpectomy of Breast","Partial Mastectomy"],"type":"PROCEDURE"},{"name":"Mastectomy","otherNames":["Mammectomy"],"type":"PROCEDURE"},{"name":"Nab-paclitaxel","otherNames":["ABI 007","ABI-007","Abraxane","Albumin-bound Paclitaxel","Albumin-Stabilized Nanoparticle Paclitaxel","Nanoparticle Albumin-bound Paclitaxel","Nanoparticle Paclitaxel","Paclitaxel Albumin","paclitaxel albumin-stabilized nanoparticle formulation","protein-bound paclitaxel"],"type":"DRUG"},{"name":"Paclitaxel","otherNames":["Anzatax","Asotax","Bristaxol","Praxel","Taxol","Taxol Konzentrat"],"type":"DRUG"},{"name":"Pertuzumab","otherNames":["2C4","2C4 Antibody","MoAb 2C4","Monoclonal Antibody 2C4","Omnitarg","Perjeta","rhuMAb2C4","RO4368451"],"type":"BIOLOGICAL"},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","Irradiate","irradiated","irradiation","RADIATION","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"],"type":"RADIATION"},{"name":"Trastuzumab","otherNames":["ABP 980","ALT02","Anti-c-ERB-2","Anti-c-erbB2 Monoclonal Antibody","Anti-ERB-2","Anti-erbB-2","Anti-erbB2 Monoclonal Antibody","Anti-HER2/c-erbB2 Monoclonal Antibody","Anti-p185-HER2","c-erb-2 Monoclonal Antibody","HER2 Monoclonal Antibody","Herceptin","Herceptin Biosimilar PF-05280014","Herceptin Trastuzumab Biosimilar PF-05280014","Herzuma","MoAb HER2","Monoclonal Antibody c-erb-2","Monoclonal Antibody HER2","Ogivri","Ontruzant","PF-05280014","rhuMAb HER2","RO0452317","SB3","Trastuzumab Biosimilar ABP 980","Trastuzumab Biosimilar ALT02","trastuzumab biosimilar EG12014","Trastuzumab Biosimilar HLX02","Trastuzumab Biosimilar PF-05280014","Trastuzumab Biosimilar SB3","Trastuzumab-dkst","Trastuzumab-dttb","Trastuzumab-pkrb","Trastuzumab-QYYP","Trazimera"],"type":"BIOLOGICAL"},{"name":"Trastuzumab Emtansine","otherNames":["Ado Trastuzumab Emtansine","ADO-Trastuzumab Emtansine","Kadcyla","PRO132365","RO5304020","T-DM1","Trastuzumab-DM1","Trastuzumab-MCC-DM1","Trastuzumab-MCC-DM1 Antibody-Drug Conjugate","Trastuzumab-MCC-DM1 Immunoconjugate"],"type":"BIOLOGICAL"}],"last_update":"2026-10-19","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-10-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recurrence-free survival (RFS)","timeFrame":"Up to 3 years after end of treatment"}],"references":[{"citation":"Tung N, Zhao F, DeMichele A, Prat A, Winer EP, Wright JL, Recht A, Weiss AC, Tjoe JA, Feldman SM, Rocque GB, Smith ML, O'Sullivan CC, Sardesai SD, Tang SC, Modi S, Irvin WJ, Unni N, Battelli C, Bagegni N, Krie AK, George MA, Telli ML, Borges VF, D'Abreo N, Shah P, Villagrasa P, Badve S, Partridge AH, Miller KD, Carey LA, Wolff AC. Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR. J Clin Oncol. 2026 Aug 20:JCO2502255. doi: 10.1200/JCO-25-02255. Online ahead of print.","pmid":"42623567","type":"DERIVED"}],"start_date":{"date":"2020-03-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy","url":"https://clinicaltrials.gov/study/NCT04266249"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/compassher2-pcr-nct04266249"}